Encorafenib 50mg, 75 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 50mg, 75 mg

Reference Brands: Braftovi (USA/EU)

Category: Oncology Cancer Care

Encorafenib is a targeted anticancer medicine classified as a BRAF kinase inhibitor. It works by blocking the activity of the mutated BRAF V600 protein, which promotes abnormal cell growth in certain cancers. Marketed under the brand name Braftovi, it is available as oral hard capsules in 50 mg and 75 mg strengths. It is mainly used for the treatment of melanoma and metastatic colorectal cancer with a BRAF V600 mutation, often in combination with other targeted therapies such as binimetinib.

Product Description:

Encorafenib inhibits mutated BRAF V600 kinase, the constitutively active protein that drives roughly half of all melanomas and a smaller but clinically distinct subset of colorectal cancers. Its pharmacological advantage over earlier BRAF inhibitors is a much longer target residence time — it stays bound to the kinase for many hours — which allows more complete and sustained pathway suppression at tolerable doses.

In melanoma it is combined with binimetinib, a MEK inhibitor, since dual blockade delays the pathway reactivation that defeats single-agent therapy. In BRAF V600E metastatic colorectal cancer it is combined with cetuximab, because that tumour escapes BRAF blockade through EGFR feedback rather than through MEK — the same drug, a different partner, dictated by different biology. Adverse effects include fatigue, arthralgia, nausea, hyperkeratosis and palmar-plantar dysaesthesia; secondary cutaneous squamous lesions require dermatological surveillance.

Sourcing notes. Originator product, on patent. It is never used alone, so demand is tied to the availability of binimetinib or cetuximab and the three are best quoted as a regimen. BRAF V600 testing is mandatory at the destination. Oral capsules in two strengths, room temperature.